Cargando…

The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries

The final text of the Trans Pacific Partnership Agreement (TPP), agreed between the 12 negotiating countries in 2016, included a suite of intellectual property provisions intended to expand and extend pharmaceutical company exclusivities on medicines. It drew wide criticism for including such provis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleeson, Deborah, Lexchin, Joel, Lopert, Ruth, Kilic, Burcu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892849/ https://www.ncbi.nlm.nih.gov/pubmed/29706802 http://dx.doi.org/10.1177/1468018117734153

Ejemplares similares

Canada and access to medicines in developing countries: intellectual property rights first
por: Lexchin, Joel
Publicado: (2013)

The Trans-Pacific Partnership Agreement: a threat to affordable medicines and public health
por: Löfgren, Hans
Publicado: (2011)

Is health impact assessment useful in the context of trade negotiations? A case study of the Trans Pacific Partnership Agreement
por: Hirono, Katherine, et al.
Publicado: (2016)

Assessing the competitiveness of solar photovoltaic products in comprehensive and progressive agreement for trans-pacific partnership countries
por: Guo, Qing, et al.
Publicado: (2023)

A new generation of trade policy: potential risks to diet-related health from the trans pacific partnership agreement
por: Friel, Sharon, et al.
Publicado: (2013)

Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere
por: Baker, Brook K.
Publicado: (2016)

The Trans-Pacific Partnership agreement and public health: Why we should be concerned
por: Schram, Ashley, et al.
Publicado: (2014)

The Trans-Pacific Partnership Agreement and health: few gains, some losses, many risks
por: Labonté, Ronald, et al.
Publicado: (2016)

What is the impact of intellectual property rules on access to medicines? A systematic review
por: Tenni, Brigitte, et al.
Publicado: (2022)

Advancing Public Health on the Changing Global Trade and Investment Agenda: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: Thow, Anne Marie, et al.
Publicado: (2016)

The Trans-Pacific Partnership: Should We "Fear the Fear"?: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: Walls, Helen L., et al.
Publicado: (2016)

Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States
por: Son, Kyung-Bok, et al.
Publicado: (2018)

Developed-developing country partnerships: Benefits to developed countries?
por: Syed, Shamsuzzoha B, et al.
Publicado: (2012)

Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
por: Gleeson, Deborah, et al.
Publicado: (2019)

Impact of the Trade-Related Aspect of Intellectual Property Rights Agreement on Pharmaceutical Industry in Developing Countries: A Scoping Review
por: Fathi, Mahdieh, et al.
Publicado: (2021)

International trade law, plain packaging and tobacco industry political activity: the Trans-Pacific Partnership
por: Fooks, Gary, et al.
Publicado: (2014)

The Dilemma of Intellectual Property Agreements and R&D in Developing Economies: A Game Theory Approach
por: El-Aroui, Mhamed-Ali, et al.
Publicado: (2021)

Critical Partnerships: How to Develop a Trans-Disciplinary Research Team
por: Waite, Kristin A., et al.
Publicado: (2023)

Developed-developing country partnerships: benefits from South to North?
por: Syed, SB, et al.
Publicado: (2011)

Is It Time to Say Farewell to the ISDS System?: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: Lencucha, Raphael
Publicado: (2016)

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014)

Factors facilitating sustainable scientific partnerships between developed and developing countries
por: Kunert, Karl J, et al.
Publicado: (2020)

European & Developing Countries Clinical Trials Partnership (EDCTP)
por: Olesen, Ole F.
Publicado: (2017)

The Practice Market : IV. Medical Partnership Agreements
Publicado: (1911)

European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership
por: Matee, Mecky I, et al.
Publicado: (2009)

Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016
por: ‘t Hoen, Ellen FM, et al.
Publicado: (2018)

Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP
por: Kanavos, Panos, et al.
Publicado: (2009)

Leadership for child health in the developing countries of the Western Pacific
por: Subhi, Rami, et al.
Publicado: (2011)

Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals
por: Gleeson, Deborah, et al.
Publicado: (2017)

European Union’s Public Fishing Access Agreements in Developing Countries
por: Le Manach, Frédéric, et al.
Publicado: (2013)

The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement
por: Motari, Marion, et al.
Publicado: (2021)

Trade Policy and Health: Adding Retrospective Studies to the Research Agenda: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: Blouin, Chantal
Publicado: (2016)

Flexibilities provided by the Agreement on Trade-Related Aspects of Intellectual Property Rights
por: Correa, Carlos M
Publicado: (2018)

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2020)

Assessing the Health Impact of Trade: A Call for an Expanded Research Agenda: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: McNamara, Courtney
Publicado: (2016)

PARTNERSHIP AGREEMENT K1496/TT/AB/007P
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2008)

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis
por: Lexchin, Joel
Publicado: (2018)

What Generates Attention to Health in Trade Policy-Making? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership
por: Townsend, Belinda, et al.
Publicado: (2020)

Just Say No to the TPP: A Democratic Setback for American and Asian Public Health: Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
por: Muntaner, Carles, et al.
Publicado: (2016)

Exploring digital trade provisions in Regional Trade Agreements (RTAs) in times of crisis: India and Asia-Pacific countries
por: Rahman, Mohd Nayyer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7b8005lkgvgd4d0djpjmbg6i7u